

CS/NSE&BSE/RPT/2020-21  
July 14, 2020

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 543064**

**Scrip Symbol: SUVENPHAR**

Dear Sir/Madam,


**Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

.....

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the year ended 31st March, 2020.

We request you to take this document on your record.

Thanking you,  
Yours faithfully,  
For **Suven Pharmaceuticals Limited**

  
**K. Hanumantha Rao**  
Company Secretary

Encl: as above

## **Suven Pharmaceuticals Limited**

***Disclosure of related party transactions on a consolidated basis***

List of related parties on consolidated basis as per Reg. 23(9)

**(a) Holding Company**

Jasti Property and Equity Holdings Private Limited  
*(Holding in its capacity as sole trustee of Jasti Family Trust)*

**(b) Subsidiaries**

Suven Pharma, Inc. (USA)

**(c) Associates**

Rising Pharma Holdings, Inc. (USA)

**(d) Key Management personnel (KMP)**

Mr. Venkateswarlu Jasti	Chairman & Managing Director
Mr. D. G. Prasad	Independent Director
Dr. Srivari Chandrasekhar	Independent Director
Ms. Deepanwita Chattopadhyay	Independent Director
Mr. J. V. Ramudu	Non-executive Director
Dr. Jerry Jeyasingh	Non-executive Director

**(e) Relative of Key Management personnel**

Mrs. Kalyani Jasti	Daughter of Mr. Venkateswarlu Jasti
--------------------	-------------------------------------

**(f) Entity with common Control**

Suven Life Sciences Limited  
Suven Neurosciences, Inc. (USA)

**Suven Pharmaceuticals Limited**

Transactions during the year ended 31 March, 2020 with related parties

*Rupees in lakhs*

Particulars	For the year ended 31 March 2020
<b>Parent entities</b>	
<ul style="list-style-type: none"> <li>• Jasti Property and Equity Holdings Private Limited <i>(Holding in its capacity as sole trustee of Jasti Family Trust)</i></li> </ul>	60.00%
<b>Subsidiaries</b>	
<ul style="list-style-type: none"> <li>• Balance outstanding</li> </ul>	24557.68
<b>Key Management Personnel compensation</b>	
<ul style="list-style-type: none"> <li>• Short term employee benefits</li> </ul>	816.75
<ul style="list-style-type: none"> <li>• Balance outstanding</li> </ul>	361.02
<b>Relative of Key Management Personnel compensation</b>	
<ul style="list-style-type: none"> <li>• Short term employee benefits</li> </ul>	271.08
<b>Entity with common Control</b>	
<ul style="list-style-type: none"> <li>• Suven Life Sciences Limited*</li> </ul>	13325.24

\* The amount relates to Inter Company loan given by Suven Life Sciences Ltd., to Suven Pharmaceuticals Ltd.

## Suven Pharmaceuticals Limited